Disparities in Adherence to National Comprehensive Cancer Network Treatment Guidelines and Survival for Stage IB-IIA Cervical Cancer in California

被引:45
|
作者
Pfaendler, Krista S.
Chang, Jenny
Ziogas, Argyrios
Bristow, Robert E.
Penner, Kristine R.
机构
[1] Univ Calif Irvine, Med Ctr, Orange, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
来源
OBSTETRICS AND GYNECOLOGY | 2018年 / 131卷 / 05期
基金
美国国家卫生研究院;
关键词
SOCIOECONOMIC-STATUS; MORTALITY-RATES; WOMEN;
D O I
10.1097/AOG.0000000000002591
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To evaluate the association of sociodemographic and hospital characteristics with adherence to National Comprehensive Cancer Network treatment guidelines for stage IB-IIA cervical cancer and to analyze the relationship between adherent care and survival. METHODS: This is a retrospective population-based cohort study of patients with stage IB-IIA invasive cervical cancer reported to the California Cancer Registry from January 1, 1995, through December 31, 2009. Adherence to National Comprehensive Cancer Network guideline care was defined by year-and stage-appropriate surgical procedures, radiation, and chemotherapy. Multivariate logistic regression, Kaplan-Meier estimate, and Cox proportional hazard models were used to examine associations between patient, tumor, and treatment characteristics and National Comprehensive Cancer Network guideline adherence and cervical cancer-specific 5-year survival. RESULTS: A total of 6,063 patients were identified. Forty-seven percent received National Comprehensive Cancer Network guideline-adherent care, and 18.8% were treated in high-volume centers (20 or more patients/year). On multivariate analysis, lowest socioeconomic status (adjusted odds ratio [OR] 0.69, 95% CI 0.57-0.84), low-middle socioeconomic status (adjusted OR 0.76, 95% CI 0.64-0.92), and Charlson-Deyo comorbidity score 1 or higher (adjusted OR 0.78, 95% CI 0.69-0.89) were patient characteristics associated with receipt of nonguideline care. Receiving adherent care was less common in low-volume centers (45.9%) than in high-volume centers (50.9%) (effect size 0.90, 95% CI 0.84-0.96). Death from cervical cancer was more common in the nonadherent group (13.3%) than in the adherent group (8.6%) (effect size 1.55, 95% CI 1.34-1.80). Black race (adjusted hazard ratio 1.56, 95% CI 1.08-2.27), Medicaid payer status (adjusted hazard ratio 1.47, 95% CI 1.15-1.87), and Charlson-Deyo comorbidity score 1 or higher (adjusted hazard ratio 2.07, 95% CI 1.68-2.56) were all associated with increased risk of dying from cervical cancer. CONCLUSION: Among patients with early-stage cervical cancer, National Comprehensive Cancer Network guideline-nonadherent care was independently associated with increased cervical cancer-specific mortality along with black race and Medicaid payer status. Nonadherence was more prevalent in patients with older age, lower socioeconomic status, and receipt of care in low-volume centers. Attention should be paid to increase guideline adherence.
引用
收藏
页码:899 / 908
页数:10
相关论文
共 50 条
  • [21] A comparison of laparoscopic radical hysterectomy and pelvic lymphadenectomy and laparotomy in the treatment of Ib-IIa cervical cancer
    Li, Guangyi
    Yan, Xiaojian
    Shang, Huilin
    Wang, Gang
    Chen, Lushi
    Han, Yubin
    GYNECOLOGIC ONCOLOGY, 2007, 105 (01) : 176 - 180
  • [22] THE EFFICACY OF ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL HYSTERECTOMY FOR INTERMEDIATE RISK STAGE IB-IIA CERVICAL CANCER
    Wang, Y.
    Lin, H.
    Lee, P.
    Huang, C.
    Wu, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A280 - A280
  • [23] The Prognostic Significance Of Pretreatment Albumin/alkaline Phosphatase Ratio In Patients With Stage IB-IIA Cervical Cancer
    Zhang, Can
    Li, Yong
    Ji, Rui
    Zhang, Weiling
    Zhang, Chenfei
    Dan, Youli
    Qian, Hongyan
    He, Aiqin
    ONCOTARGETS AND THERAPY, 2019, 12 : 9559 - 9568
  • [24] Prospective multicenter study on urologic complications after radical surgery with or without radiotherapy in the treatment of stage IB-IIA cervical cancer
    Zola, P
    Maggino, T
    Sacco, M
    Rumore, A
    Sinistrero, G
    Maggi, R
    Landoni, F
    Foglia, G
    Sartori, E
    De Toffoli, J
    Franchi, M
    Romagnolo, C
    Sismondi, P
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2000, 10 (01) : 59 - 66
  • [25] Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update
    Landoni, Fabio
    Colombo, Alessandro
    Milani, Rodolfo
    Placa, Franco
    Zanagnolo, Vanna
    Mangioni, Costantino
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (03)
  • [26] Preoperative work-up of early cervical cancer - (Stages Ib-IIa)
    Kokka, F
    Vorgias, G
    Tserkezoglou, A
    Tsiaousi, I
    Hadjiieleftheriou, G
    Andriotis, M
    Akrivos, T
    Fotiou, S
    Apostolikas, N
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2003, 24 (02) : 175 - 177
  • [27] Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage IB-IIA cervical cancer
    Behtash, N.
    Nazari, Z.
    Ayatollahi, H.
    Modarres, M.
    Ghaemmaghmi, F.
    Mousavi, A.
    EJSO, 2006, 32 (10): : 1226 - 1230
  • [28] Does adherence to National Comprehensive Cancer Network (NCCN) practice guidelines improve survival?
    Clair, Kiran
    Tanjasiri, Sora
    Bristow, Robert
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [29] Proteomic Identification of Neoadjuvant Chemotherapy-Related Proteins in Bulky Stage IB-IIA Squamous Cervical Cancer
    Zou, Shuangwei
    Shen, Qi
    Hua, Ying
    Jiang, Wenxiao
    Zhang, Wenwen
    Zhu, Xueqiong
    REPRODUCTIVE SCIENCES, 2013, 20 (11) : 1356 - 1364
  • [30] Different types of hysterectomy in the radio-surgical treatment of early cervical cancer (FIGO Ib-IIa)
    Zola, P
    Ferrero, A
    Fuso, L
    Jacomuzzi, ME
    Magistris, A
    Spanu, P
    Mazzola, S
    Sinistrero, G
    Sismondi, P
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2002, 23 (03) : 236 - +